Drug Type Small molecule drug |
Synonyms- |
Target |
Mechanism ADAR inhibitors(adenosine deaminase RNA specific inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Accent Therapeutics, Inc.Startup |
Active Organization Accent Therapeutics, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Small Cell Lung Cancer | Preclinical | US | Accent Therapeutics, Inc.Startup | 20 Apr 2024 |
Ovarian Cancer | Preclinical | US | Accent Therapeutics, Inc.Startup | 20 Apr 2024 |
Squamous Cell Carcinoma of Head and Neck | Preclinical | US | Accent Therapeutics, Inc.Startup | 20 Apr 2024 |
Triple Negative Breast Cancer | Preclinical | US | Accent Therapeutics, Inc.Startup | 20 Apr 2024 |